The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis
CONCLUSION: The introduction of the CGRP mAbs during 2018 resulted in a decrease in utilization of most oral medications and onabotulinumtoxinA for the prevention of migraine. Future work should continue to observe how the prescription patterns of these medications evolve with time.PMID:37882379 | DOI:10.1111/head.14642 (Source: Headache)
Source: Headache - October 26, 2023 Category: Neurology Authors: Leon S Moskatel Anna Graber-Naidich Zihuai He Niushen Zhang Source Type: research
Understanding the links between airborne hazards and headache disorders
Headache. 2023 Oct 26. doi: 10.1111/head.14648. Online ahead of print.NO ABSTRACTPMID:37882325 | DOI:10.1111/head.14648 (Source: Headache)
Source: Headache - October 26, 2023 Category: Neurology Authors: Elizabeth K Seng Andrea H Weinberger Source Type: research
The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis
CONCLUSION: The introduction of the CGRP mAbs during 2018 resulted in a decrease in utilization of most oral medications and onabotulinumtoxinA for the prevention of migraine. Future work should continue to observe how the prescription patterns of these medications evolve with time.PMID:37882379 | DOI:10.1111/head.14642 (Source: Headache)
Source: Headache - October 26, 2023 Category: Neurology Authors: Leon S Moskatel Anna Graber-Naidich Zihuai He Niushen Zhang Source Type: research
Understanding the links between airborne hazards and headache disorders
Headache. 2023 Oct 26. doi: 10.1111/head.14648. Online ahead of print.NO ABSTRACTPMID:37882325 | DOI:10.1111/head.14648 (Source: Headache)
Source: Headache - October 26, 2023 Category: Neurology Authors: Elizabeth K Seng Andrea H Weinberger Source Type: research
The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis
CONCLUSION: The introduction of the CGRP mAbs during 2018 resulted in a decrease in utilization of most oral medications and onabotulinumtoxinA for the prevention of migraine. Future work should continue to observe how the prescription patterns of these medications evolve with time.PMID:37882379 | DOI:10.1111/head.14642 (Source: Headache)
Source: Headache - October 26, 2023 Category: Neurology Authors: Leon S Moskatel Anna Graber-Naidich Zihuai He Niushen Zhang Source Type: research
Understanding the links between airborne hazards and headache disorders
Headache. 2023 Oct 26. doi: 10.1111/head.14648. Online ahead of print.NO ABSTRACTPMID:37882325 | DOI:10.1111/head.14648 (Source: Headache)
Source: Headache - October 26, 2023 Category: Neurology Authors: Elizabeth K Seng Andrea H Weinberger Source Type: research
The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis
CONCLUSION: The introduction of the CGRP mAbs during 2018 resulted in a decrease in utilization of most oral medications and onabotulinumtoxinA for the prevention of migraine. Future work should continue to observe how the prescription patterns of these medications evolve with time.PMID:37882379 | DOI:10.1111/head.14642 (Source: Headache)
Source: Headache - October 26, 2023 Category: Neurology Authors: Leon S Moskatel Anna Graber-Naidich Zihuai He Niushen Zhang Source Type: research
Understanding the links between airborne hazards and headache disorders
Headache. 2023 Oct 26. doi: 10.1111/head.14648. Online ahead of print.NO ABSTRACTPMID:37882325 | DOI:10.1111/head.14648 (Source: Headache)
Source: Headache - October 26, 2023 Category: Neurology Authors: Elizabeth K Seng Andrea H Weinberger Source Type: research
The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis
CONCLUSION: The introduction of the CGRP mAbs during 2018 resulted in a decrease in utilization of most oral medications and onabotulinumtoxinA for the prevention of migraine. Future work should continue to observe how the prescription patterns of these medications evolve with time.PMID:37882379 | DOI:10.1111/head.14642 (Source: Headache)
Source: Headache - October 26, 2023 Category: Neurology Authors: Leon S Moskatel Anna Graber-Naidich Zihuai He Niushen Zhang Source Type: research
Evaluating therapeutic benefits of ubrogepant via latent class models: A post hoc exploratory analysis of the ACHIEVE I and ACHIEVE II trials
CONCLUSION: The LCM approach led to higher rates of treatment success and greater separation between ubrogepant and placebo and was a more sensitive predictor of treatment satisfaction than the regulatory endpoint of 2hPF.PMID:37873925 | DOI:10.1111/head.14631 (Source: Headache)
Source: Headache - October 24, 2023 Category: Neurology Authors: Charlie J Iaconangelo Daniel Serrano Aubrey Manack Adams Joel M Trugman Richard B Lipton Source Type: research
Hypermobility spectrum disorders and migraine in adolescents
Headache. 2023 Oct 24. doi: 10.1111/head.14650. Online ahead of print.NO ABSTRACTPMID:37873975 | DOI:10.1111/head.14650 (Source: Headache)
Source: Headache - October 24, 2023 Category: Neurology Authors: Chia-Chun Chiang Source Type: research
Caution regarding fabricated citations from artificial intelligence
Headache. 2023 Oct 24. doi: 10.1111/head.14649. Online ahead of print.NO ABSTRACTPMID:37873980 | DOI:10.1111/head.14649 (Source: Headache)
Source: Headache - October 24, 2023 Category: Neurology Authors: Fred Cohen Jenn Vallimont Amy A Gelfand Source Type: research
Evaluating therapeutic benefits of ubrogepant via latent class models: A post hoc exploratory analysis of the ACHIEVE I and ACHIEVE II trials
CONCLUSION: The LCM approach led to higher rates of treatment success and greater separation between ubrogepant and placebo and was a more sensitive predictor of treatment satisfaction than the regulatory endpoint of 2hPF.PMID:37873925 | DOI:10.1111/head.14631 (Source: Headache)
Source: Headache - October 24, 2023 Category: Neurology Authors: Charlie J Iaconangelo Daniel Serrano Aubrey Manack Adams Joel M Trugman Richard B Lipton Source Type: research
Hypermobility spectrum disorders and migraine in adolescents
Headache. 2023 Oct 24. doi: 10.1111/head.14650. Online ahead of print.NO ABSTRACTPMID:37873975 | DOI:10.1111/head.14650 (Source: Headache)
Source: Headache - October 24, 2023 Category: Neurology Authors: Chia-Chun Chiang Source Type: research
Caution regarding fabricated citations from artificial intelligence
Headache. 2023 Oct 24. doi: 10.1111/head.14649. Online ahead of print.NO ABSTRACTPMID:37873980 | DOI:10.1111/head.14649 (Source: Headache)
Source: Headache - October 24, 2023 Category: Neurology Authors: Fred Cohen Jenn Vallimont Amy A Gelfand Source Type: research
